Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Vir Biotechnology, Inc. (VIR) Balance Sheet

As of 2026-06-30 (10-Q), Vir Biotechnology, Inc. (VIR) reported total assets of $1.2B, total liabilities of $232.3M and shareholders' equity of $982.5M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $278.7M.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

VIRVir Biotechnology, Inc.Follow VIR — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
1.8B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
4 Nov, in 11 days
LineFY2019
Dec 19
FY2020
Dec 20
FY2021
Dec 21
FY2022
Dec 22
FY2023
Dec 23
FY2024
Dec 24
FY2025
Dec 25
Latest
Jun 26
Trend
Cash and equivalents0.110.440.350.850.240.220.230.28
Short-term investments0.270.300.221.521.270.680.230.25
Receivables—0.000.770.00————
Current assets0.400.771.562.521.591.040.510.57
Total assets0.510.921.952.801.921.401.001.21
Current liabilities0.060.100.340.510.180.120.090.09
Total liabilities0.090.200.520.720.330.250.240.23
Shareholders' equity0.420.721.432.081.591.150.770.98

USD billions · SEC XBRL

Vir Biotechnology, Inc. — questions

How much cash does Vir Biotechnology, Inc. have?
$278.7M in cash and cash equivalents as of 2026-06-30.
What are Vir Biotechnology, Inc.'s total assets?
$1.2B as of 2026-06-30.
What is Vir Biotechnology, Inc.'s shareholders' equity?
$982.5M as of 2026-06-30.

Every figure on this page comes from Vir Biotechnology, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.